KBY Biotech Indexv0.0.34
Search
← Pipeline|SVA-6795

SVA-6795

NDA/BLA
By Sinovac
Source: Trial-derived·Trials: 1
Modality
Small Molecule
MOA
EGFRi
Target
CDK4/6
Pathway
Notch
CRCNB
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
~Jul 2021
→ ~Oct 2022
Phase 3
~Jan 2023
→ ~Apr 2024
NDA/BLA
Jul 2024
→ Jan 2028
NDA/BLACurrent
NCT03020533
1,718 pts·NB
2024-07→2028-01·Active
1,718 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-071.8y awayPh3 Readout· NB
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
NDA/BLA
Active
Catalysts
Ph3 Readout
2028-01-07 · 1.8y away
NB
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03020533NDA/BLANBActive1718CfB
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
GSK-2051GSKPhase 1PSMAEGFRi
MotavorutinibAmgenPhase 3CDK4/6JAK1/2i
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
RibozanubrutinibRegeneronPhase 1CDK4/6IL-13i
MRN-5715ModernaNDA/BLACDK4/6AuroraAi
207-2754Samsung BiologicsPhase 1/2KRASG12DEGFRi
MavuratamabBlueprint MedicinesNDA/BLABETEGFRi
BemaderotideRevolution MedicinesPhase 3BCL-2EGFRi